Walgreens Boots Alliance

Is Walgreens Boots Alliance publicly traded?
Walgreens Boots Alliance is currently publicly traded on Nasdaq under the ticker symbol WBA. However, in March 2025, Sycamore Partners announced an agreement to acquire the company for approximately $23.7 billion including debt, which would take WBA private. The deal was expected to close by the end of 2025, subject to shareholder and regulatory approval.

Who is acquiring Walgreens Boots Alliance?
Sycamore Partners, a New York-based private equity firm specializing in retail and consumer investments, announced an agreement in March 2025 to acquire WBA for approximately $23.7 billion including debt. WBA shareholders would receive $11.45 per share in cash, plus contingent value rights tied to the healthcare services businesses.

Who is the CEO of Walgreens Boots Alliance?
Tim Wentworth is the CEO of Walgreens Boots Alliance. He was appointed in October 2023, having previously served as CEO of Express Scripts and Cigna's Evernorth health services division. Wentworth has led the company's turnaround strategy, including store closures and scaling back the VillageMD investment.

What is Walgreens Boots Alliance's revenue?
Walgreens Boots Alliance reported FY2024 revenue of $147.7 billion (fiscal year ended August 31, 2024). The company reported a net loss of $8.8 billion, primarily due to a $5.8 billion VillageMD impairment charge and other goodwill write-downs. Adjusted EBITDA was approximately $4.1 billion.

Why is Walgreens closing stores?
Walgreens announced plans to close approximately 1,200 underperforming U.S. stores as part of a turnaround strategy. The closures reflect declining retail pharmacy margins, competition from online retailers, and the need to optimize the company's physical footprint. The closures have raised concerns about pharmacy access in underserved communities.

What is VillageMD?
VillageMD is a primary care provider in which Walgreens Boots Alliance holds a majority stake. WBA invested $5.2 billion in VillageMD in 2021 with plans to open co-located clinics inside Walgreens stores. The investment has struggled financially, resulting in a $5.8 billion impairment charge in FY2024. WBA has announced plans to reduce its stake in VillageMD.

When was Walgreens Boots Alliance founded?
Walgreens Boots Alliance was formed on December 31, 2014, through the merger of Walgreens and Alliance Boots. Walgreens was founded in 1901 by Charles R. Walgreen Sr. in Chicago. Boots was founded in 1849 by John Boot in Nottingham, England.

Walgreens traces its origins to 1901 when Charles R. Walgreen Sr. purchased a drug store in Chicago. The company grew throughout the 20th century, becoming one of the largest pharmacy chains in the United States through organic growth and strategic acquisitions, including the acquisition of Duane Reade in 2010 for $1.1 billion.

Alliance Boots was formed in 2006 through the merger of Alliance UniChem and Boots Group. Boots was founded in 1849 by John Boot in Nottingham, England, and grew into one of the UK's leading pharmacy and health and beauty retailers. Alliance UniChem was a European pharmaceutical wholesale and retail company.

In 2012, Walgreens acquired a 45 percent stake in Alliance Boots for $6.7 billion, with an option to acquire the remaining stake. Walgreens completed the full acquisition of Alliance Boots on December 31, 2014, creating Walgreens Boots Alliance. The combined company became the first global pharmacy-led health and wellness retailer.

In the years following the merger, WBA pursued expansion into healthcare services. In 2021, the company invested $5.2 billion in VillageMD, a primary care provider, with plans to open Village Medical clinics co-located with Walgreens stores. In 2022, WBA acquired CareCentrix, a post-acute care management company, for $1.7 billion. The company also acquired Shields Health Solutions, a specialty pharmacy provider.

However, the healthcare services investments struggled. VillageMD faced financial losses and slower-than-expected clinic growth. In 2024, WBA announced it would reduce its stake in VillageMD and significantly scale back the co-located clinic strategy. The company took a $5.8 billion impairment charge related to VillageMD in FY2024.

In 2024, WBA sold its stake in Guoda Drugstores, its China joint venture, and announced it was reviewing its international portfolio. The company also began closing underperforming U.S. stores, with approximately 1,200 store closures announced.

In March 2025, Sycamore Partners announced its agreement to acquire WBA for approximately $23.7 billion including debt, representing one of the largest private equity acquisitions of a healthcare company. The deal would take WBA private, providing the company with flexibility to execute its turnaround strategy without public market scrutiny.

Walgreens Boots Alliance has set science-based targets for emissions reduction and has implemented sustainability initiatives focused on energy efficiency, waste reduction, and sustainable product sourcing. The company has committed to reducing its carbon footprint across its global operations.

However, the company's sustainability programs have been overshadowed by its financial challenges and the pending Sycamore acquisition. The company's environmental reporting has been less prominent in recent quarters as management has focused on the turnaround strategy.

WBA's primary ethical considerations relate to pharmacy practices, medication safety, and healthcare access. The company maintains compliance programs for pharmaceutical distribution and retail pharmacy operations. The opioid settlement and ongoing scrutiny of pharmacy practices represent significant ethical and regulatory challenges.

Walgreens Boots Alliance has faced significant regulatory and legal challenges in recent years. The company was a defendant in opioid-related litigation, resulting in a $5.7 billion settlement in 2022 with states and local governments for its role in distributing opioid medications.

The company has faced scrutiny over prescription drug pricing and its relationships with pharmacy benefit managers. WBA has been involved in discussions and regulatory proceedings regarding drug pricing transparency and reimbursement rates.

The VillageMD investment has drawn criticism from investors who questioned the strategic rationale and financial returns of the primary care expansion. The $5.8 billion impairment charge in FY2024 validated concerns about the investment's value.

The company's store closure program has raised concerns about pharmacy access in underserved communities, particularly in rural and low-income urban areas where Walgreens may be the only nearby pharmacy. Critics have argued that closing stores in these areas creates pharmacy deserts, reducing access to prescription medications and healthcare services.

The Sycamore Partners acquisition has faced scrutiny from labor unions and consumer advocates concerned about potential job cuts and reduced services under private equity ownership. Sycamore has defended the deal, emphasizing its commitment to strengthening WBA's core pharmacy business.